Using a murine mammary fat pad xenograft model of human HER2-positive DCIS, a direct murine intra-ductal administration model [15], and a chick embryo xenograft model, we demonstrate that JAM-A functional antagonism using a novel JAM-A-binding peptide hinders tumor progression. Here, ERBB2 is linked to ductal breast carcinoma in situ.